Clinical Trial Update: A Study to Evaluate SHR-1210 in Subjects With Advanced HCC [Phase 2]

View source ↗

Summary

Phase 2 trial of SHR-1210 in advanced hepatocellular carcinoma (non-resectable) completed with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• SHR-1210 (camrelizumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Hepatocellular Carcinoma Non-Resectable | Phase 2 | Status: COMPLETED | Results posted: 2024-03-15